Santa Ana Bio Inc. has emerged from stealth with $168 million in combined series A and B funding and a focus on developing targeted therapies for patients with autoimmune and inflammatory diseases.
At the ongoing EULAR meeting, Nektar Therapeutics Inc. presented the first preclinical data on its anti-TNFR2 agonist antibody – NKTR-0165 – for the potential treatment of autoimmune and chronic inflammatory diseases.
Santa Ana Bio Inc. launched with combined series A and B rounds that pulled down $168 million for its precision immunology push in inflammatory diseases, with an aim of entering the clinic next year across several fronts.
Acepodia Inc.’s antibody cell conjugation platform could change the way CAR T-cell therapies are manufactured, clearing the way for an off-the-shelf model to treat numerous cancers that is safer and cheaper than current CAR Ts, Acepodia CEO Sonny Hsiao told BioWorld.
Acepodia Inc.’s antibody cell conjugation platform could change the way CAR T-cell therapies are manufactured, clearing the way for an off-the-shelf model to treat numerous cancers that is safer and cheaper than current CAR Ts, Acepodia CEO Sonny Hsiao told BioWorld.
Excessive inflammatory response and endothelial barrier dysfunction are the two major pathophysiological changes in acute respiratory distress syndrome (ARDS). Sphingosine-1-phosphate S1P3 receptor (S1PR3) is a G protein-coupled receptor involved in the regulation of inflammation and vascular barrier function in some diseases, but its function in ARDS is not fully understood.
An expert in hepatitis delta virus said Vir Biotechnology Inc.’s phase II findings with the monoclonal antibody tobevibart and the small interfering ribonucleic acid elebsiran in chronic disease could lead to a “change [in] the entire care cascade and paradigm.” Shares of Vir (NASDAQ:VIR) ended June 5 at $12.66, up $2.08, or 19.7%, on the clinical news.
Researchers from Shanghai Jiao Tong University presented findings from a study that aimed to assess the metabolic landscape of intestinal fibrosis in Crohn’s disease.
C-C chemokine receptor type 6 (CCR6) regulates the migration and recruitment of T cells in inflammatory and immunological processes and, as part of the CCR6-CCL20 axis together with its exclusive binding molecule CCL20, plays a critical role in maintaining immunological homeostasis during inflammation and infection.
RSS
